Theratechnologies Inc T.TH

Stay focused on the facts

[SPCEO1]

What we want from the phase 1a is an indication that TH-1902 has a future. We just want to know that it is not a bust as that would certainly be bad for TH. But I don't even think we have to wait for that to be confirmed by the company as they have already functionally confirmed that TH-1902 has a future. How bright that future will be is yet to be determined but it is a drug that is moving onto the next phase of FDA testing, indicating it is safe. That is the first hurdle all drugs have to jump and based on the planning TH is already engaged in for not only phase 1b but phase 2 trials, they clearly know with a high degree of certainty the drug is moving forward. So, we will be talking about TH-1902 for a while here. 

I believe the inclusion of the additional data on the trial slide of the most recent corporate presentation also functionally confirms that TH-1902 worked to some degreee on at least patient 2. Indeed, that is probably why they put that presentation update out - to give us confidence that TH-1902 is on track. So, if patient number 2 saw some benefit, and they almost had to or they would not have gone through 4 rounds of testing, then we can check another box off with a high degree of confidence - that of proof of concept. From the beginning we worried that because of t he way the trial was structured we might not see that in the phase 1a, but I think you can take it to the bank now that at least one patient reactedin some positive way to the drug which indicated TH-1902 was indeed getting into cancer cells and having some level of impact. Time will tell just how extensive that impact will be but clearly something positive was going on with patient 2. I am not expecting the benefit for patient 2 to be substantial since the trial was not geared to determine benefit and most of the doses given were at the lower level, but we don't need substantial benefit at this point. We just need to know that TH-1902 worked something like it was supposed to based on the pre-clinical work.

So, for any of you who are stressing out because the share price is falling and you think something terrible has happened, I would suggest you think hard about what the company has actually already revealed to us about the pahse 1a and realize that we already know in general terms that the drug is safe enough to move forward to phase 1b and that it showed some degree of benefit in at least one patient which indicates it is working as expected. 

Stock prices sometimes get drunk and act stupid in the short term. They are therefore often a really bad source of critical information about the long term situation yet many people still listen to the drunk rather than factual data staring them right in the face. Don't be that person as you will likely really regret it.

[Momo25]

The drunk is the one who is looking at his wealth vanishing while he thinks it's just an impression. I am a business guy. If market knows all the goods you are mentioning for a while, why it is ignoring such good opportunity.? You are the one who misleaded the shareholders and you continue to do so.

[Trogarzon]

Maybe the seller is the one that will look and feel really bad in not too long. I recall the pre Egrifta approval period in 20210.... the seller sued Thera for their losses.

[Momo25]

I bought THTX when Trogarzo was lunched. At that time Dubuc talked about a potential of at least 1 billion revenue. Then everything becomes inconsistent. Legacy drugs are covering for the costs only. NASH needs huge investment and big pharmas who are making money like ever are reluctant to put a penny in this program. Oncology was brought to the table since they bought katana and the results up to

[canadapiet]

And they lied again!!!!!!! They said the P1a all went smoothly, just like in the preclinicals............! Look at where we are now.......... How long are the "people in the know" saying that there is "HOPE" ????? Well, let us all "HOPE" that in the near future (?????again....) we can set a new high !!  Momo25 - (3/23/2022 9:54:30 AM

[PWIB123]

Did they actually say all went smoothly?  I don't recall hearing that, especially considering they released and acknowledged the neutropenia.  I do remember them saying that the things they were seeing were consistent with preclinical. 

[Biobob]

If we can just fill the rogue seller and get back to business.  I would expect Soleus to grab the opportunity if they are still beleivers in Th1902.  It is pure stupidity sometimes.  I client of mine switched brokers in 2017 and called me when Th was 10$+ in dismay... the other guy sold at 2$ his 320 000 shares... hope it's the case for this imbecile next year.

[jfm1330]

They were way off on timelines. Back last June they were talking about reaching MTD at the begining od the fall, so October. Then they revised it to begining of 2022. And now it's something like May 2022. You want to know why the SP is down. You cannot be so bad in your guidance on timelines. Add they changed their tune on NASH and stagnant commercial business. I am glad they changed their

[SPCEO1]

Good post. That better explains the pickle they have got themselves in regarding the narrative they have created around the stock price. As you point out, they really cannot control very well what the FDA insists upon but they could have sold the whole thing to the market better by setting better expectations, especially since almost all drug trials go longer than initially expected. And I have to

[jfm1330]

On the commercial side, we need to recognize that Levesque got bad timing with Covid. It's hard to judge him properly on that because of this situation. Their NASH and oncology strategy was related. My guess is that they were very optimistic last June about phase Ia of TH1902. Expected good results published in october or November, and a rise in the SP following that. If the rise and the

[qwerty22]

plus the general flight from biotech which has had some really good commentators in the sector scratching their head.

[jfm1330]

I should add that the main problem now, at least for somebody able to understand the science, is that we have no hint at all about the proof of concept. 300 mg/m2 (1.3 times MTD of docetaxel alone) could be possible without a proof of concept. That mean a 300 mg/m2 could be tolerated by patients even if TH1902 is not internalized inside cancer cells by sortilin. A 300 mg/m2 could be tolerated just

[juniper88]

Yes, "we" [the people reading this board] do not have much of a hint of proof of concent.  Perhaps, patient #2 being on the treatment for 4 cycles could be considered a "hint".  Either way, the investiigators might have hints that we simple do not know about.  And these hints might have startted at lower doses than 300mg/m2.  If I am right about patient #2

[jfm1330]

You are right that 300 mg/m2 could be a good dose, but it would be the case only with a proof of concept. Also, yes having the highest possible dosage is not a necissity, if you have the proof of concept. As I said in my previous message, at this point if the 420 mg/m2 was the MTD, it would be in itself a very strong indication that we have a proof of concept because I think it would be impossible

[juniper88]

I don't believe that patient #2 was stopped at cycle 4. The chart simply doesn't put the dashed boxes beyond the 300mg/m2 level.

[qwerty22]

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3201164/ Here's a paper that compares Trop2 expression in normal cells versus cancer cells. It's the target for Trodelvy that Gilead paid $21 billion for and did nearly $400 million in sales last year on it's so far very limited label. If you read that paper, which I assume somebody at Gilead did, you might wonder how it ever got approved

[Wino115]

I agree --this seems fairly typical for most ADC trials I've read about as they just leave the chemo near the environment and not into the targeted tumor. For whatever reason, eye issues seem to be prevalent with ADCs, along with the usual lists.  I believe that's why Trodelvy had a long setback in the 1b/2a timeframe and had to rework a number of issues. 

[gossamer7]

This post has been removed in accordance with Community Policy

[SPCEO1]

I can't remember off the top of my head if they specifically said all was going smoothly but they certainly alluded to that being the case. But seeing neutropenia is what the phase 1a was looking for so seeing it would be normal. Basically a dose escalation study is trying to determine how much of a drug can be tolerated before trouble arises so finding things  like neutrpenia is the goal

[qwerty22]

I have all sorts of rambling things to say. I'll keep it short. I just don't think they've publicly attempted to talk about the therapeutic window. I think what they've done is shed light on the decision making process that has defined how the trial has progressed (decisions around the 420/300 doses) and what are the next steps (6 more patients). That process is driven by toxicity

[SPCEO1]

I think I know what the therapeutic window is but I also know when it comes to the science, I really don't know what i don't know. So, would you be so kind as to give us a short primer on what t he therapeutic window is and what ideally we should be looking for on that front from the phase 1a trial?

[qwerty22]

I think it's just what you understand they are doing with the dose escalation but by a different name. Put simply it's the dose range where you get the therapeutic response you are looking for while still having acceptable toxicity. In my view they haven't much described that. Formally speaking 420 didn't hit 2 DLTs but it seems a clinical judgement was made that this is a dose too

[juniper88]

Quick note about neutropeniia.  Patients that go on trials are patients who have had many cycles of chemo.  These chemo cycle have a very bad effect on the patients' bone marrow.  It is actually difficult to tell at this stage if any neutropenia is because of the current treatment or because of past treatments.   As someof you might know my wife is now on a different

[Bucknelly21]

Can't imagine being in your situation juniper prays to you and the wife

[jfm1330]

They lied??? Come on. People here cry about the lack of promotion. Imagine if the would be promotional.

[SPCEO1]

If what we have already heard about TH-1902 is suggestive of better things to come, and it probably is, then new highs will be achieved. But this will be a process. We already have very good indications of safety and proof of concept which sets the stage for the next step in phase 1b (if not in phase 1a) of preliminary indications of efficacy. If TH-1902 works and is safe, it has a big future and

[SPCEO1]

Just because you have suffered losses does not define the reality of what TH is or may become. Science defines that. You are reacting emotionally and that is not a good sign for you as itoften leads to bad choices.  Look at the science and what the company has already revealed about TH-1902, not your previous bad decisions.

[SPCEO1]

And lost their suit as well. Don't be that person.

[SPCEO1]

I challenge you to get specific with how I have misled shareholders. And I will be happy to respond to your assertions. And then maybe we will look back at what you have said and we can see if what you said was backed up by facts too. Seems fair, right?